JP4361800B2 - 心不全を処置するための組成物および方法 - Google Patents

心不全を処置するための組成物および方法 Download PDF

Info

Publication number
JP4361800B2
JP4361800B2 JP2003559423A JP2003559423A JP4361800B2 JP 4361800 B2 JP4361800 B2 JP 4361800B2 JP 2003559423 A JP2003559423 A JP 2003559423A JP 2003559423 A JP2003559423 A JP 2003559423A JP 4361800 B2 JP4361800 B2 JP 4361800B2
Authority
JP
Japan
Prior art keywords
pyridin
phenyl
fluoro
yloxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003559423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514432A5 (enExample
JP2005514432A (ja
Inventor
ファディー マリック，
アダム ルイス トマシ，
バイニアン フェン，
エリカ アンネ クレイナック，
キャスリーン エリアス，
プ−ピン ル，
ウィットニー ウォルター スミス，
シャンピン チャン，
デービッド ジェイ． ジュニア モーガンズ，
Original Assignee
サイトキネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトキネティックス， インコーポレイテッド filed Critical サイトキネティックス， インコーポレイテッド
Publication of JP2005514432A publication Critical patent/JP2005514432A/ja
Publication of JP2005514432A5 publication Critical patent/JP2005514432A5/ja
Application granted granted Critical
Publication of JP4361800B2 publication Critical patent/JP4361800B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003559423A 2001-12-21 2002-12-20 心不全を処置するための組成物および方法 Expired - Lifetime JP4361800B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34308801P 2001-12-21 2001-12-21
PCT/US2002/040996 WO2003059258A2 (en) 2001-12-21 2002-12-20 Compositions and methods for treating heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004324438A Division JP2005068160A (ja) 2001-12-21 2004-11-08 心不全を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2005514432A JP2005514432A (ja) 2005-05-19
JP2005514432A5 JP2005514432A5 (enExample) 2005-12-22
JP4361800B2 true JP4361800B2 (ja) 2009-11-11

Family

ID=23344654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003559423A Expired - Lifetime JP4361800B2 (ja) 2001-12-21 2002-12-20 心不全を処置するための組成物および方法
JP2004324438A Withdrawn JP2005068160A (ja) 2001-12-21 2004-11-08 心不全を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004324438A Withdrawn JP2005068160A (ja) 2001-12-21 2004-11-08 心不全を処置するための組成物および方法

Country Status (6)

Country Link
US (3) US6908923B2 (enExample)
EP (1) EP1503986B1 (enExample)
JP (2) JP4361800B2 (enExample)
AU (1) AU2002367023A1 (enExample)
CA (1) CA2470427C (enExample)
WO (1) WO2003059258A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495337B1 (en) * 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
JP4361800B2 (ja) * 2001-12-21 2009-11-11 サイトキネティックス， インコーポレイテッド 心不全を処置するための組成物および方法
EP1615878B1 (en) * 2003-01-14 2012-04-04 Cytokinetics, Inc. Compounds, compositions and methods of treatment for heart failure
WO2006009726A2 (en) 2004-06-17 2006-01-26 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
KR20160058972A (ko) 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
MX2007004248A (es) * 2004-10-13 2007-06-12 Merck Patent Gmbh Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2011035174A1 (en) 2009-09-17 2011-03-24 Vanderbilt University Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
US9844542B2 (en) 2013-11-19 2017-12-19 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
CA3075669A1 (en) 2017-09-13 2019-03-21 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
EP3740481B9 (en) 2018-01-19 2024-10-23 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
CN119954787A (zh) 2018-04-18 2025-05-09 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
TW202315628A (zh) * 2021-06-24 2023-04-16 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055905A (en) 1958-03-04 1962-09-25 Geigy Chem Corp New sulphamyl benzamides
US3447922A (en) * 1964-12-28 1969-06-03 Xerox Corp Electrically photosensitive particles useful in photoelectrophoretic and xerographic imaging processes
US3577550A (en) * 1968-05-02 1971-05-04 Dow Chemical Co N-(phenoxy)phenyl-salicylamides and their utilization as molluscidides
US3674850A (en) 1969-12-07 1972-07-04 Lever Brothers Ltd Substituted salicylanilides
DE2248662A1 (de) 1972-10-04 1974-04-18 Bayer Ag Loesliche aromatische copolyamide und daraus hergestellte faeden mit hohem elastizitaetsmodul und hoher reissfestigkeit
DE3139457A1 (de) 1981-10-03 1983-04-21 Bayer Ag, 5090 Leverkusen Neue substituierte benzanilidether, verfahren zu ihrer herstellung, ihre verwendung als fungizide und zwischenprodukte hierfuer
FR2601015B1 (fr) 1986-07-04 1988-08-05 Rhone Poulenc Sante Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH02115839A (ja) 1988-10-26 1990-04-27 Fuji Photo Film Co Ltd ハロゲン化銀カラー感光材料
JPH0717594B2 (ja) 1989-01-25 1995-03-01 久光製薬株式会社 新規なスルホンアニリド誘導体
JP2795519B2 (ja) 1990-04-11 1998-09-10 三井化学株式会社 芳香族ポリアミド
JP2821564B2 (ja) 1991-05-29 1998-11-05 住化ファインケム株式会社 キナゾリノン誘導体の製造方法
FR2687574B1 (fr) 1992-02-25 1995-05-05 Rhone Poulenc Rorer Sa Nouvelle application therapeutique de derives du pyridylpyrrolothiazole carboxamide.
WO1994022830A1 (en) * 1993-03-31 1994-10-13 Smithkline Beecham Corporation Chemical compounds
US6001379A (en) 1993-09-15 1999-12-14 L'oreal Stable acidic oil-in- water type emulsions and compositions containing them
SK27198A3 (en) * 1995-08-30 1998-09-09 Bayer Ag Acylaminosalicylic acid amides and their uses as pesticides
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US6143472A (en) * 1998-11-18 2000-11-07 Wako Pure Chemical Industries, Ltd. Resist composition and a method for formation of a pattern using the composition
AR015514A1 (es) * 1998-02-10 2001-05-02 Novartis Ag Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene
GB9822238D0 (en) 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
ES2546386T3 (es) 1999-07-20 2015-09-23 Dow Agrosciences, Llc Amidas aromáticas heterocíclicas fungicidas y sus composiciones, métodos de uso y preparación
DE60039115D1 (de) 1999-08-20 2008-07-17 Dow Agrosciences Llc Fungizide heterocyclische aromatische amide und deren zusammensetzungen, verfahren zu deren anwendung und herstellung
DE10010002A1 (de) 2000-03-02 2001-09-06 Celanese Ventures Gmbh Verfahren zur Nitrierung und Aminierung von Arylpolymer
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
KR20020089493A (ko) * 2000-04-28 2002-11-29 상꾜 가부시키가이샤 ＰＰＡＲγ모듈레이터
DE10110002B4 (de) 2001-03-01 2006-03-09 Georg Oswald Lange Toilettensitz
AU2002367953C1 (en) 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
ATE541847T1 (de) 2001-11-01 2012-02-15 Icagen Inc Pyrazolopyrimidine als natriumkanalblocker
JP4361800B2 (ja) * 2001-12-21 2009-11-11 サイトキネティックス， インコーポレイテッド 心不全を処置するための組成物および方法
EP1535610A4 (en) 2002-06-10 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC CANCER
EA010470B1 (ru) 2002-06-10 2008-08-29 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
EA011707B1 (ru) 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний

Also Published As

Publication number Publication date
AU2002367023A8 (en) 2003-07-30
EP1503986A2 (en) 2005-02-09
US6908923B2 (en) 2005-06-21
US20050148638A1 (en) 2005-07-07
CA2470427C (en) 2012-07-10
CA2470427A1 (en) 2003-07-24
WO2003059258A2 (en) 2003-07-24
US7605164B2 (en) 2009-10-20
EP1503986B1 (en) 2015-09-30
AU2002367023A1 (en) 2003-07-30
WO2003059258A3 (en) 2004-11-11
JP2005068160A (ja) 2005-03-17
US20030158233A1 (en) 2003-08-21
EP1503986A4 (en) 2005-11-30
US7053094B2 (en) 2006-05-30
JP2005514432A (ja) 2005-05-19
US20060173024A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
JP4361800B2 (ja) 心不全を処置するための組成物および方法
EP1765327B1 (en) Compounds, compositions and methods
JP4613157B2 (ja) 化合物、組成物および方法
US8101620B2 (en) Heterocyclic sulfonamides
RU2337094C2 (ru) Ацилированные арилциклоакиламины и их применение в качестве фармацевтических средств
US20090192168A1 (en) Compounds, Compositions and Methods
EP1959960B1 (en) Certain chemical entities, compositions and methods
EP1959962A2 (en) Certain chemical entities, compositions, and methods
CN101821279A (zh) 某些化学个体、组合物和方法
CN107207489A (zh) 作为nadph氧化酶抑制剂的酰氨基噻二唑衍生物
US7910743B2 (en) Compounds, compositions and methods
JP5178526B2 (ja) 化合物、組成物および方法
US20030158186A1 (en) Compositions and methods for treating heart failure
WO2007070626A2 (en) Certain chemical entities, compositions and methods
JP2008508285A (ja) カリウムチャンネル阻害剤
CN113015736B (zh) 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
HK1085461B (en) Compounds, compositions and methods of treatment for heart failure
HK1101060B (en) Compounds, compositions and methods

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20090127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090722

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090813

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4361800

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120821

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120821

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130821

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term